Thermo Fisher, Daiichi Sankyo to develop NSCLC test

By staff writers

June 24, 2020 -- Thermo Fisher Scientific and Daiichi Sankyo have agreed to co-develop a companion test for patients with non-small cell lung cancer (NSCLC).

Their collaboration will focus on identifying HER2 gene mutations using Thermo Fisher's next-generation sequencing-based Oncomine Dx Target test. The companion test will be used to identify patients eligible for treatment with trastuzumab deruxtecan (Enhertu), a HER2 directed antibody drug conjugate developed by Daiichi Sankyo and Astra Zeneca that is currently in global phase II development for HER2-mutated or HER2-overexpressing NSCLC.

Thermo Fisher will retain rights to commercialize the test globally and will seek approval from regulatory agencies. This announcement follows a 2018 agreement between the companies to expand the clinical utility of the test in support of clinical trials and drug development programs at Daiichi Sankyo.

Thermo Fisher glioma companion test gets breakthrough designation
The U.S. Food and Drug Administration has granted breakthrough device designation to Thermo Fisher Scientific for its assay to identify two key mutations...
Q2 Solutions, Thermo Fisher partner on oncology testing
Thermo Fisher Scientific and clinical trial laboratory company Q2 Solutions are partnering on a plan to reduce the turnaround time for laboratory tests...
Thermo Fisher, WuXi, Mayo Clinic to develop COVID-19 test
Thermo Fisher Scientific announced it is working with WuXi Diagnostics and Mayo Clinic to develop a COVID-19 antibody test.
Thermo Fisher bee sting allergy test clears FDA
Thermo Fisher Scientific has received U.S. Food and Drug Administration clearance for its ImmunoCap Specific Immunoglobulin E Stinging Insect Allergen...

Copyright © 2020

Last Updated ls 6/24/2020 2:29:06 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.